Evidence map›Paper›PMID 24696846›Full record

ReviewBioMed research international2014

Interleukin-10 inhibits bone resorption: a potential therapeutic strategy in periodontitis and other bone loss diseases.

Qian Zhang, Bin Chen, Fuhua Yan, Jianbin Guo, Xiaofeng Zhu, Shouzhi Ma, Wenrong Yang

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 5 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 5 syntheses or guidelines pooled it, 220 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Qian ZhangInstitute and Hospital of Stomatology, Nanjing University Medical School, 30 Zhongyang Road, Nanjing, Jiangsu 210008, China.ORCID 0000-0003-0412-5014
Bin ChenInstitute and Hospital of Stomatology, Nanjing University Medical School, 30 Zhongyang Road, Nanjing, Jiangsu 210008, China.ORCID 0000-0001-8690-1835
Fuhua YanInstitute and Hospital of Stomatology, Nanjing University Medical School, 30 Zhongyang Road, Nanjing, Jiangsu 210008, China.ORCID 0000-0001-5632-9487
Jianbin GuoSchool and Hospital of Stomatology, Fujian Medical University, 246 Yangqiaozhong Road, Fuzhou, Fujian 350002, China.
Xiaofeng ZhuSchool and Hospital of Stomatology, Fujian Medical University, 246 Yangqiaozhong Road, Fuzhou, Fujian 350002, China.
Shouzhi MaSchool and Hospital of Stomatology, Fujian Medical University, 246 Yangqiaozhong Road, Fuzhou, Fujian 350002, China.
Wenrong YangSchool of Life and Environmental Science, Waurn Ponds Campus, Deakin University, 75 Pigdons Road, Geelong, VIC 3216, Australia.
Fujian Medical University · CNNanjing Medical University · CNDeakin University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Periodontitis and other bone loss diseases, decreasing bone volume and strength, have a significant impact on millions of people with the risk of tooth loss and bone fracture. The integrity and strength of bone are maintained through the balance between bone resorption and bone formation by osteoclasts and osteoblasts, respectively, so the loss of bone results from the disruption of such balance due to increased resorption or/and decreased formation of bone. The goal of therapies for diseases of bone loss is to reduce bone loss, improve bone formation, and then keep healthy bone density. Current therapies have mostly relied on long-term medication, exercise, anti-inflammatory therapies, and changing of the life style. However there are some limitations for some patients in the effective treatments for bone loss diseases because of the complexity of bone loss. Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine, and recent studies have indicated that IL-10 can contribute to the maintenance of bone mass through inhibition of osteoclastic bone resorption and regulation of osteoblastic bone formation. This paper will provide a brief overview of the role of IL-10 in bone loss diseases and discuss the possibility of IL-10 adoption in therapy of bone loss diseases therapy.

Indexed as

AnimalsBone and BonesBone ResorptionHumansInterleukin-10PeriodontitisInterleukin-10

Identifiers

PMID24696846
PMCPMC3947664
OpenAlexW2094349968

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.